824982-19-6

Basic information

• Product Name: 3,8-Diazabicyclo[3.2.1]octane-8-carboxylic acid, 3-(2,2,2-trifluoroacetyl)-, 1,1-diMethylethyl ester
• Synonyms: 3,8-Diazabicyclo[3.2.1]octane-8-carboxylic acid, 3-(2,2,2-trifluoroacetyl)-, 1,1-diMethylethyl ester;tert-Butyl 3-(2,2,2-trifluoroacetyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
• CAS NO: 824982-19-6
• Molecular Formula: C₁₃H₁₉F₃N₂O₃
• Molecular Weight: 308.2967696
• Mol File: 824982-19-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3,8-Diazabicyclo[3.2.1]octane-8-carboxylic acid, 3-(2,2,2-trifluoroacetyl)-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3,8-Diazabicyclo[3.2.1]octane-8-carboxylic acid, 3-(2,2,2-trifluoroacetyl)-, 1,1-diMethylethyl ester(824982-19-6)
• EPA Substance Registry System: 3,8-Diazabicyclo[3.2.1]octane-8-carboxylic acid, 3-(2,2,2-trifluoroacetyl)-, 1,1-diMethylethyl ester(824982-19-6)

Safety Data

• Hazardous Substances Data: 824982-19-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3,8-Diazabicyclo[3.2.1]octane-8-carboxylic acid, 3-(2,2,2-trifluoroacetyl)-, 1,1-diMethylethyl ester is used as a catalyst or reagent in organic synthesis, particularly in the field of polymerization. It facilitates various reactions such as the formation of polyurethane foams and coatings.
Used in Laboratory Research:
DABCO-2-TF is utilized by chemists and researchers in a laboratory setting for the development of new materials and pharmaceuticals. Its unique properties make it a valuable tool for selective functionalization and derivatization of organic molecules.

Upstream product

• 149771-44-8 8-t-butoxycarbonyl-3,8-diazabicyclo[3.2.1]octane 
• 407-25-0 trifluoroacetic anhydride 
• 824982-18-5 1-(8-Benzyl-3,8-diaza-bicyclo[3.2.1]oct-3-yl)-2,2,2-trifluoro-ethanone 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 93428-56-9 8-benzyl-3,8-diazabicyclo[3.2.1]octane 
• 149771-44-8 8-t-butoxycarbonyl-3,8-diazabicyclo[3.2.1]octane 

Relevant articles and documents

PYRROLOPYRIDAZINE INHIBITORS OF IRAK4 ACTIVITY

The present invention relates to pyrrolopyridazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS

Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Substituted diazabicycloakane derivatives

Compounds of formula (I) Z-Ar1—Ar2??(I) wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from an unsubstituted or substituted 5-membered heteroaryl ring; an unsubstituted or substituted 6-membered heteroaryl ring; 3,4-(methylenedioxy)phenyl; and phenyl substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

Novel amides useful for treating pain

The present invention relates to compounds of formula (I) that useful in treating pain.

Novel amides useful for treating pain

The present invention relates to compounds of formula (I-VII) or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R6, R7 and R8 are defined herein. The present invention also relates to methods of trating pain using these compounds and pharmaceutical compositions including these compounds.